Option delistings effective August 19th include Assembly Biosciences (ASMB), Bio-Path Holdings (BPTH), Cyclacel Pharmaceuticals (CYCC), MSP Recovery Inc (LIFW), Northern Star Investment Corp II (NSTB), Natura &co Holding S.a. (NTCOY), Nuvve Holding Corp (NVVE), TNF PHARMACEUTICALS, INC (TNFA), Tusimple Holdings Inc (TSPH), Titan Pharmaceuticals (TTNP), and Uxin Ltd (UXIN).
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASMB:
- Assembly Biosciences reports Q2 EPS ($1.98) , one estimate ($2.23)
- Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates
- ASMB Earnings this Week: How Will it Perform?
- Assembly Biosciences presents preclinical data of investigational HSV portfoli
- Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop